CRAD-BC-Rad AB (publ)
34.90SEK-0.29%Mkt Cap: 110.10M $P/E: 23.58

C-Rad AB (publ) develops, manufactures, and sells products and systems with applications in radiotherapy for the treatment of cancer in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company off…

HeadlineSourceTime
Older
EEFN
C-Rad AB (FRA:24C) Q4 2025 Earnings Call Highlights: Navigating Growth and Challenges

Despite strong growth in the Americas and improved gross margins, C-Rad AB faces regional challenges and increased operating expenses.

GuruFocus.com
C-Rad AB (FRA:24C) Q3 2025 Earnings Call Highlights: Strong Service Growth Amidst Regional ...

C-Rad AB (FRA:24C) reports robust service revenue growth and improved operating margins, despite facing market uncertainties in the Americas and APEC regions.

GuruFocus.com
C-Rad (OM:CRAD B) Net Margin Drops to 5.1%, Challenging Bullish Growth Narratives

C-Rad (OM:CRAD B) reported a notable dip in net profit margin to 5.1% from 11.9% last year, but the bigger picture tells a growth story. Over the past five years, the company averaged 25.7% annual earnings growth and is now forecasting an impressive 62.9% yearly increase moving forward. Revenue is also projected to climb 11.2% per year, handily outpacing the broader Swedish market’s 3.3% pace. With margins compressed but growth prospects running well ahead of the market, this latest update...

Simply Wall St.